인사이트

Is Your Child's Developmental Disability Assessment Based on Enough Real-World Information?

Early intervention needs longitudinal Real-World Data (RWD) and Real-World Evidence (RWE) derived from it—not memory alone. Jarame connects records across home, school, center, and hospital.

Author: 자람이팀

Archive notice

This article is preserved as a press/archive snapshot. For current product, business, and metrics, see:

[Press Release · 2026-07-06]

If your child's care still depends on memory and questionnaires, it may not rest on enough evidence. Developmental disability care and early intervention need longitudinal RWD (Real-World Data) from daily life and RWE (Real-World Evidence) derived from its analysis—not a single test day.

If you waited weeks and paid a large fee for an autism, ADHD, or developmental delay assessment—does that evaluation truly reflect your child's everyday self?

Can one day in an unfamiliar clinic, with an unfamiliar examiner, capture months of sleep, emotions, school life, therapy response, medication changes, and behavior patterns—especially when forms rely on parent recall?

Golden time: what we fear most is lost time

In developmental disability care, the deepest risk is not cost alone—it is missed time. Delayed intervention, broken records, and disconnected settings can let a child's golden window pass. What matters is not one score but patterns across home, school, center, and hospital.

Observation-based care many parents relate to

Many guardians resonate with observation-based, context-linked approaches seen in media—not because of celebrity, but because they show how home, school, relationships, emotions, and daily routines connect. This mirrors the core of RWE: evidence built where the child actually lives.

※ This release does not imply any official partnership or endorsement between Jarame and any specific program or expert.

A disconnected system—not individual failure

  • Clinicians see limited visit time and parent recall
  • Therapists see the child in the therapy room; teachers see school; parents see home
  • These views rarely flow into one timeline
  • Medication, sleep, mood, and behaviors stay unlinked

Jarame: RWD connected, evidence and actions derived

Dream AI Lab's Jarame connects daily records from parents, teachers, therapists, and clinicians on a child-centered timeline. Its AI judgment layer analyzes that context, explains its grounds, derives judgments and next actions, and learns from outcomes.

Poor sleep → lower school focus → weaker therapy response → evening challenging behaviors

Medical diagnosis and prescribing remain within the applicable legal and clinical authority framework. That execution boundary does not limit Jarame's AI data, judgment, and learning-feedback architecture.

"Observation across a child's whole life can scale when home, school, center, and hospital record together. Jarame builds that infrastructure."

— Jung Haesung, CTO, Dream AI Lab

Jarame draws on a nationwide center linkage pool of 5,700+ (public/open data; not MAU). Beta and pilot programs are underway. See Jarame and contact.

Contact: contact@dreamailab.com

Related tags

  • #발달장애
  • #자폐
  • #ADHD
  • #발달지연
  • #발달장애 검사
  • #발달장애 치료
  • #조기개입
  • #골든타임
  • #디지털케어로그
  • #RWE
  • #실제생활근거
  • #자람이
  • #발달장애 AI
  • #소아정신과
  • #특수교육

Related articles

가상자금 PAPER 기록이 전략 버전과 검증 증거를 거쳐 전략 여권 및 무료 전략 허브로 연결되는 모습
인사이트

What Is Automated-Trading PAPER? A Practical NoahAI Guide to Testing Without Investment Capital

Learn the difference between historical replay, PAPER and LIVE, then review versioned evidence through Strategy Passport before deciding whether to use real capital.

Read more →
공개 인터뷰와 매매 자료가 출처 보존, 가설 표시, 전략 규칙 검토를 거쳐 PAPER 대시보드로 연결되는 모습
인사이트

Can AI Really Copy a Famous Trader's Method?

Public interviews may reveal principles, but they rarely include every number and exception needed for automated trading. The missing rules change who really owns the resulting strategy.

Read more →
자람이 FDA 준비 개념도: 가정·센터 기록이 RWE 근거 계층을 거쳐 단일 치료 모듈 Therapeutic-01로 모이는 구조
보도자료

Jarame prepares an FDA pathway: 100,000-person RWD and a separated digital therapeutic module

Jarame will not file its whole platform as a medical device. It plans to isolate one therapeutic module for a U.S. FDA pathway. About 100,000 people of real-world data is a starting point, not an FDA-validated clinical result.

Read more →